Xiao Huang
Director/Miembro de la Junta en CUTIA THERAPEUTICS .
Perfil
Xiao Huang has held various director positions at CBMG Holding AB, Shanghai Yunfeng Investment Management Co. Ltd., Sironax Ltd., and Cutia Therapeutics (Shanghai) Co., Ltd.
He is currently a Director at CBMG Holding AB and a Managing Director at Shanghai Yunfeng Investment Management Co. Ltd.
Additionally, he serves as a Non-Executive Director at Cutia Therapeutics and MicroPort Cardiac Rhythm Management International Ltd.
Dr. Huang obtained a doctorate degree from Yale University in 2012 and an undergraduate degree from Tsinghua University in 2007.
Cargos activos de Xiao Huang
Empresas | Cargo | Inicio |
---|---|---|
CUTIA THERAPEUTICS | Director/Miembro de la Junta | 26/08/2020 |
Cutia Therapeutics (Shanghai) Co., Ltd.
Cutia Therapeutics (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Cutia Therapeutics, Cutia Therapeutics (Shanghai) Co., Ltd. develops therapeutics to treat severe facial acne vulgaris. The private company is based in Shanghai, China. The Chinese company was founded in 2019. The CEO is Le Le Zhang. | Director/Miembro de la Junta | - |
Shanghai Yunfeng Investment Management Co. Ltd.
Shanghai Yunfeng Investment Management Co. Ltd. Investment ManagersFinance Shanghai Yunfeng Investment Management Co. Ltd (Yunfeng Capital) is a private equity firm founded in 2010 by Feng Yu and Yun Ma. The firm is headquartered in Shanghai, China. | Corporate Officer/Principal | 01/05/2015 |
Sironax Ltd.
Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Director/Miembro de la Junta | - |
MicroPort Cardiac Rhythm Management International Ltd.
MicroPort Cardiac Rhythm Management International Ltd. Financial ConglomeratesFinance MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong. | Director/Miembro de la Junta | 28/04/2020 |
CBMG Holding AB | Director/Miembro de la Junta | 01/02/2021 |
Formación de Xiao Huang.
Yale University | Doctorate Degree |
Tsinghua University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
CUTIA THERAPEUTICS | Health Technology |
Empresas privadas | 5 |
---|---|
CBMG Holding AB | |
Shanghai Yunfeng Investment Management Co. Ltd.
Shanghai Yunfeng Investment Management Co. Ltd. Investment ManagersFinance Shanghai Yunfeng Investment Management Co. Ltd (Yunfeng Capital) is a private equity firm founded in 2010 by Feng Yu and Yun Ma. The firm is headquartered in Shanghai, China. | Finance |
Sironax Ltd.
Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Health Technology |
Cutia Therapeutics (Shanghai) Co., Ltd.
Cutia Therapeutics (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Cutia Therapeutics, Cutia Therapeutics (Shanghai) Co., Ltd. develops therapeutics to treat severe facial acne vulgaris. The private company is based in Shanghai, China. The Chinese company was founded in 2019. The CEO is Le Le Zhang. | Health Technology |
MicroPort Cardiac Rhythm Management International Ltd.
MicroPort Cardiac Rhythm Management International Ltd. Financial ConglomeratesFinance MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong. | Finance |
- Bolsa de valores
- Insiders
- Xiao Huang